Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.36 |
| ▸ | HTR2A | P28223 | 11/20 | 0.36 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25320684 | 1.00 | HTR2C (0.36) | HTR2CHTR2AAPLNRCYP1A2CYP3A4 | |
| SCHEMBL30550753 | 1.00 | HTR2C (0.36) | HTR2CHTR2AAPLNRCYP1A2CYP3A4 | |
| SCHEMBL25321744 | 0.84 | AAK1 (0.35) | APLNRPSMB1PSMB5 | |
| SCHEMBL25321749 | 0.84 | AAK1 (0.35) | APLNRPSMB1PSMB5 | |
| SCHEMBL31058397 | 0.84 | AAK1 (0.35) | APLNRPSMB1PSMB5 | |
| SCHEMBL31362912 | 0.79 | HTR2C (0.42) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25320614 | 0.75 | TIPARP (0.34) | — | |
| SCHEMBL25321537 | 0.73 | HDAC3 (0.37) | PSMB1PSMB5 | |
| SCHEMBL25321540 | 0.73 | HDAC3 (0.37) | PSMB1PSMB5 | |
| SCHEMBL31388974 | 0.72 | PSMB1 (0.36) | HTR2CHTR2APSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | HTR2C 1861/4885HTR2A 2837/4885APLNR 3634/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | HTR2C 1861/4885HTR2A 2837/4885APLNR 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.